Skip to content

Study · Not a test of the peptide alone · 2008

6 results

Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men.

Paulo RC, Cosma M, Soares-Welch C, Bailey JN, Mielke KL, Miles JM, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism11 Dec 2007Cited by 4 (Europe PMC)

PMID18073313 (opens in a new tab)PMCIDPMC2266948 (opens in a new tab)DOI10.1210/jc.2007-1388 (opens in a new tab)PepBankPUB-18073313
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    The negative effect of BMI on peak GH responses differed between eugonadal and hypogonadal states most markedly after GHRH plus GHRP‑2.

    In plain wordsIn healthy young men, the link between body mass index and growth hormone response differed by hormone state, most clearly after GHRH and GHRP‑2 together.

    Peptide
    GHRP-2
    Outcome
    MixedDifference in BMI effect on peak GH between eugonadal and hypogonadal states after GHRH/GHRP-2
    Study

    n = 22

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The negative effects of BMI on peak GH responses in eugonadal and hypogonadal states differed most markedly after stimulation with GHRH/GHRP-2 (P=0.0019).
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    The contrast between eugonadal and hypogonadal states in the BMI effect was corroborated using integrated GH responses.

    In plain wordsIn healthy young men, the same difference between hormone states showed up when total growth hormone output was measured.

    Peptide
    GHRP-2
    Outcome
    MixedDifference in BMI effect on integrated GH responses between eugonadal and hypogonadal states
    Study

    n = 22

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    This contrast was corroborated using integrated GH responses (P=0.0007).
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    In eugonadal healthy men, peak GH concentrations after secretagogue infusion correlated negatively with BMI.

    In plain wordsIn healthy young men with normal hormone levels, a higher body mass index went with a lower peak growth hormone response.

    Peptide
    GHRP-2
    Outcome
    Not applicablePeak GH versus BMI in eugonadal men
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In eugonadal men, peak GH concentrations correlated negatively with BMI.
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    In eugonadal men, BMI accounted for 62% of the variability in the peak GH response after GHRH plus GHRP‑2.

    In plain wordsIn healthy young men with normal hormones, body mass index explained most of the variation in growth hormone response to GHRH with GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    Not applicableVariance in peak GH explained by BMI after GHRH/GHRP-2 in eugonadal men
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Response variability explained by BMI
    62%
    eugonadal men, GHRH/GHRP-2

    Source sentences

    Summary
    but 62% after GHRH/GHRP-2 (P=0.0012)
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 05HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    In eugonadal men, BMI accounted for 65% of the variability in the peak GH response after L-arginine plus GHRP‑2.

    In plain wordsIn healthy young men with normal hormones, body mass index explained most of the variation in growth hormone response to L-arginine with GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    Not applicableVariance in peak GH explained by BMI after L-arginine/GHRP-2 in eugonadal men
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Response variability explained by BMI
    65%
    eugonadal men, L-arginine/GHRP-2

    Source sentences

    Summary
    65% after L-arginine/GHRP-2 (P=0.00075)
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  6. 06HumanNot a test of GHRP-2 aloneRandomized controlled trialOther

    In experimentally hypogonadal men, GH responses were uncorrelated with BMI.

    In plain wordsIn healthy young men with experimentally lowered sex hormones, body mass index was not linked to the growth hormone response.

    Peptide
    GHRP-2
    Outcome
    No significant changePeak GH versus BMI in hypogonadal men
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In contrast, in hypogonadal men, GH responses were uncorrelated with BMI.
    1 context sentence
    Summary · context
    Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.